The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells

American Journal of Pathology

Volumn 174, Issue 6, 2009, Pages 2150-2159

  Lesma, Elena ^a,d   Sirchia, Silvia Maria ^a   Ancona, Silvia ^a   Carelli, Stephana ^a   Bosari, Silvano ^a,c   Ghelma, Filippo ^a   Montanari, Emanuele ^a   Di Giulio, Anna Maria ^a   Gorio, Alfredo ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d Pharmacological Laboratories   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; EPIDERMAL GROWTH FACTOR; RAPAMYCIN; TRICHOSTATIN A; TUBERIN;

ADULT; ANGIOMYOLIPOMA; ARTICLE; CASE REPORT; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; LEIOMYOMATOSIS; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; SMOOTH MUSCLE; TUBEROUS SCLEROSIS;

EID: 67049164007     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080799     Document Type: Article

References (44)

1. Young J, Povey S: The genetic basis of tuberous sclerosis. Mol Med Today 1998, 4:313-319 (Pubitemid 28364109)
2. Neumann HP, Schwarzkopf G, Henske EP: Renal angiomyolipomas, cysts, and cancer in tuberous sclerosis complex. Semin Pediatr Neurol 1998, 5:269-275 (Pubitemid 29011302)
3. European Chromosome 16 Tuberous Sclerosis Consortium: Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993, 75:1305-1315
4. van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Jansen B, Verhoef S, Lindhout D, van den Ouweland A, Halley D, Young J, Burley M, Jeremiah S, Woodward K, Nahmias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S, Snell RG, Cheadle JP, Jones AC, Tachataki M, Ravine D, Sampson JR, Reeve MP, Richardson P, Wilmer F, Munro C, Hawkins TL, Sepp T, Ali JB, Ward S, Green AJ, Yates JR, Kwiatkowska J, Henske EP, Short MP, Haines JH, Jozwiak S, Kwiatkowski DJ: Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997, 277:805-808 (Pubitemid 27366729)
5. Benvenuto G, Li S, Brown SJ, Braverman R, Vass WC, Cheadle JP, Halley DJ, Sampson JR, Wienecke R, DeClue JE: The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 2000, 19:6306-6316 (Pubitemid 32641844)
6. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, Thomas G: Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 2003, 11:1457-1466 (Pubitemid 36776533)
7. Inoki K, Li Y, Xu T, Guan KL: Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003, 17:1829-1834 (Pubitemid 36944560)
8. Inoki K, Corradetti MN, Guan KL: Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005, 37:19-24 (Pubitemid 40070934)
9. Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin-Kowalik J, Kotulska K, Kwiatkowski DJ: Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 2004, 63:1236-1242 (Pubitemid 39603395)
10. Henske EP, Scheithauer BW, Short MP, Wollmann R, Nahmias J, Hornigold N, van Slegtenhorst M, Welsh CT, Kwiatkowski DJ: Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet 1996, 59:400-406 (Pubitemid 26266356)
11. Niida Y, Stemer-Rachamimow AO, Logrip M, Tapon D, Perez R, Kwiatkowski DJ, Sims K, MacCollin M, Louis DN, Ramesh V: Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet 2001, 69:493-503 (Pubitemid 32777689)
12. Au KS, Hebert AA, Roach ES, Northrup H: Complete inactivation of the TSC2 gene leads to formation of hamartomas. Am J Hum Genet 1999, 65:1790-1795 (Pubitemid 30468695)
13. Cheadle J, Reeve M, Sampson J, Kwiatkowski D: Molecular genetic advances in tuberous sclerosis complex. Hum Genet 2000, 107:97-104 (Pubitemid 30686962)
14. Ng HH, Bird A: DNA methylation and chromatin modification. Curr Opin Genet Dev 1999, 9:158-163 (Pubitemid 29158549)
15. Razin A: CpG methylation, chromatin structure and gene silencing-a three-way connection. EMBO J 1998, 17:4905-4908 (Pubitemid 28408457)
16. El-Hashemite N, Walker V, Kwiatkowski DJ: Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: a tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Cancer Res 2005, 65:2474-2481 (Pubitemid 40490160)
17. Pacheco-Rodriguez G, Steagall WK, Crooks DM, Stevens LA, Hashimoto H, Li S, Wang JA, Darling TN, Moss J: TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis. Cancer Res 2007, 67:10573-10581 (Pubitemid 350070834)
18. Lesma E, Grande V, Lesma E, Carelli S, Brancaccio D, Canevini MP, Alfano RM, Coggi G, Di Giulio AM, Gorio A: Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma: EGF is the required growth factor. Am J Pathol 2005, 167:1093-1103 (Pubitemid 41416260)
19. Carelli S, Lesma E, Paratore S, Grande V, Zadra G, Di Giulio AM, Gorio A: Survivin expression in tuberous sclerosis complex cells. Mol Med 2007, 13:166-177 (Pubitemid 46944959)
20. Arbiser JL, Yeung R, Weiss SH, Arbiser ZK, Amin MB, Cohen C, Frank D, Mahajan S, Herron GS, Yang J, Onda H, Zhang HB, Bai X, Uhlmann E, Loehr A, Northrup H, Au P, Davis I, Fisher DE, Gutmann DH: The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma. Am J Pathol 2001, 159:483-491
21. Jones AC, Sampson JR, Hoogendoorn B, Cohen D, Cheadle JP: Application and evaluation of denaturing HPLC for molecular genetic analysis in tuberous sclerosis. Hum Genet 2000, 106:663-668 (Pubitemid 30427022)
22. Gilbert SL, Sharp PA: Promoter-specific hypoacetylation of X-inactivated genes. Proc Natl Acad Sci USA 1999, 96:13825-13830
23. Sirchia SM, Ferguson AT, Sironi E, Subramanyan S, Orlandi R, Sukumar S, Sacchi N: Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells. Oncogene 2000, 19:1556-1563 (Pubitemid 30175677)
24. Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, Toma S, Nicolò G, Sacchi N: Endogenous reactivation of the RAR beta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res 2002, 62:2455-2461
25. Sirchia SM, Ramoscelli L, Grati FR, Barbera F, Cordini D, Rossella F, Porta G, Lesma E, Ruggeri A, Radice P, Simoni G, Miozzo M: Loss of the inactive X chromosome and replication of the active X in BRCA1 effective and wild-type breast cancer cells. Cancer Res 2005, 65:2139-2146 (Pubitemid 40490120)
26. -/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM. PLoSONE 2008, 3:e3558
27. Henske EP, Wessner LL, Golden J, Scheithauer BW, Vortmeyer AO, Zhuang Z, Klein-Szanto AJ, Kwiatkowski DJ, Yeung RS: Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of the tuberous sclerosis tumors. Am J Pathol 1997, 151:1639-1647 (Pubitemid 27527926)
28. Tapon N, Ito N, Dickson BJ, Treisman JE, Hariharan IK: The drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 2001, 105:345-355 (Pubitemid 32455341)
29. Hengstschläger M, Rodman DM, Miloloza A, Hengstschlager-Ottnad E, Rosner M, Kubista M: Tuberous sclerosis gene products in proliferation control. Mutat Res 2001, 488:233-239 (Pubitemid 32521034)
30. Carsillo T, Astrinidis A, Henske EP: Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000, 97:6085-6090 (Pubitemid 30367527)
31. Koptides M, Mean R, Demetriou K, Pierides A, Deltas CC: Genetic evidence for a trans-heterozygous model for cytogenesis in autosomal dominant polycystic kidney disease. Hum Mol Genet 2000, 9:447-452 (Pubitemid 30098739)
32. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995, 1:686-692
33. Toyooka S, Toyooka KO, Miyajima K, Reddy JL, Toyota M, Sathyanarayana UG, Padar A, Tockman MS, Lam S, Shivapurkar N, Gazdar AF: Epigenetic down-regulation of death-associated protein kinase in lung cancers. Clin Cancer Res 2003, 9:3034-3041 (Pubitemid 36993264)
34. Holliday R, Pugh JE: DNA modification mechanism and gene activity during development. Science 1975, 187:226-232
35. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998, 72:141-196
36. Jones PA, Laird PW: Cancer epigenetics come to age. Nat Genet 1999, 21:163-167
37. Jiang WG, Sampson J, Martin TA, Lee-Jones L, Watkins G, Douglas- Jones A, Mokbel K, Mansel RE: Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. Eur J Cancer 2005, 41:1628-1636 (Pubitemid 40981846)
38. Chakraborty S, Mohiyuddin SMA, Gopinath KS, Kumar A: Involvement of TSC genes and differential expression of other members of the mTOR signalling pathway in oral squamous cell carcinoma. BMC Cancer 2008, 8:163-175 (Pubitemid 351891408)
39. Bi G, Jiang G: The molecular mechanism of HDAC inhibitors in anticancer effects. Cell Mol Immunol 2006, 3:285-290
40. Marks PA, Breslow R: Dimethyl sulfoxide to varinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007, 25:84-90 (Pubitemid 46087907)
41. Bissler J, McCormack FX, Young LR, Elwing JM, Chuck G: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008, 358:140-151
42. Vokes EE, Chu E: Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology 2006, 20(5 Suppl 2):15-25
43. Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, Sun Y, Schmidt K, Albert MS, El-Hashemite N, Lader AS, Onda AS, Zhang H, Kwiatkowski DJ, Dabora SL: Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse model. Genes Chromosom Cancer 2005, 42:213-227 (Pubitemid 40171186)
44. Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M, Kwiatkowski DJ: Response of a neural model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 2008, 28:5422-5432